Michael Newton, MD
Critical Care Medicine · Tampa, FLNPI 1114024247
Payments from drug & device makers
Across 76 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$317
- GSK$311
- Philips North America LLC$229
- Insmed, Inc.$212
- Jazz Pharmaceuticals Inc.$164
- Inspire Medical Systems, Inc.$152
- plus $674 from 14 others
What the payments were for
- Food & beverage$1,84990%
- Education$21010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $317 |
| GSK | 15 | $311 |
| Philips North America LLC | 12 | $229 |
| Insmed, Inc. | 7 | $212 |
| Jazz Pharmaceuticals Inc. | 4 | $164 |
| Inspire Medical Systems, Inc. | 1 | $152 |
| Bayer | 1 | $115 |
| 3b Medical, Inc. | 2 | $79 |
| Gilead | 1 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $68 |
| Johnson & Johnson | 1 | $66 |
| Amgen | 2 | $53 |
| Baxter Healthcare | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 1 | $42 |
| Resmed Corp | 2 | $33 |
| Boehringer Ingelheim | 2 | $30 |
| Shire North American Group Inc | 2 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Pfizer | 1 | $14 |
| Electromed, Inc. | 3 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire Upper Airway Stimulation System$152
- SUNOSI$125
- BREZTRI$123
- TRELEGY ELLIPTA$120
- Kerendia$115
How this compares
$2,059 in reported general payments places this provider in the 75th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 45 | $572,963 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 209 | $199,181 |
| Spiriva RespimatTiotropium Bromide | 89 | $65,420 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $35,482 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $31,377 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $20,648 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $19,750 |
| EliquisApixaban | 19 | $15,666 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $15,184 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 430 | $14,261 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $13,766 |
| XareltoRivaroxaban | 13 | $10,854 |
| Arnuity ElliptaFluticasone Furoate | 35 | $9,401 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $8,292 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $7,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $30 | $659,031163 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $311 | $273,475363 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga | $317 | $56,970100 claims |
| PfizerEliquis | $14 | $15,66619 claims |
| Johnson & JohnsonXarelto | $66 | $10,85413 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $42 | $5,93416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Tampa
- Debabrata BandyopadhyayTampa$1.9M
- Jeffrey LevyHollywood$19M
- Ahmad AswadMiami$6.6M
- George DuvallVero Beach$6M
- Fortune AlabiKissimmee$3.2M
- Carlos VacaMiami$3M
- Christopher HardenGainesville$713K
- Fred UmehKissimmee$682K
- Ali AtayaGainesville$672K
- George AzarFt Lauderdale$669K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.